Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? - Wikidata - awgldk - TriplyDB

Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?

Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?

http://www.wikidata.org/entity/Q37392869

about

Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.Efavirenz in the therapy of HIV infection.Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings.Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial.The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.Absence seizures associated with efavirenz initiation Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children 24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167.Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.Antiretroviral therapy for children in resource-limited settings: current regimens and the role of newer agents.Pharmacokinetics of Efavirenz at a High Dose of 25 Milligrams per Kilogram per Day in Children 2 to 3 Years Old.Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients.Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.A 33-year-old patient with human immunodeficiency virus on antiretroviral therapy with efavirenz-induced complex partial seizures: a case report.Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO.Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.

P2860

Q33593775-8662F1ED-E3C7-42BA-A639-DF4D42439ECA Q33607011-2D1EF178-A6D9-4C7C-AFE9-8D2B73982125 Q33914723-A2558B20-307D-4078-A991-7309BCA28A80 Q34083071-45240BC6-82B7-4F41-86DA-0218CA5E0FFA Q34571594-04DF7DCF-FE30-41BB-98AD-B82231882397 Q34997616-D9B24975-5748-465E-8176-8F1C088C7E80 Q35154032-AE943BCC-60F7-4595-B9D7-6F61176682AE Q35547048-5164BBDE-B0A7-4556-ACD5-017D3FE08CB1 Q35752638-6B966656-C518-46F5-9CE6-080A44DD20D5 Q36306986-B683F564-68A1-47BB-ADB5-400F56BDE4EA Q37030715-7693CD04-080D-4405-A539-8DE78CDBBE66 Q37299209-39669632-DB72-4A58-B0CE-705B4E17123D Q37429325-75B99850-4A69-41B6-81A4-5480F200734A Q37519804-DA125899-BB77-4232-B494-5AA554205D68 Q37544540-A7AD4199-E470-4D99-B135-0431637F7555 Q37835819-93BFDBD5-001E-4FC9-95BB-F06038293C1D Q37866289-C3015BE2-008C-4D8C-B0CD-114B835EA3F2 Q37925813-D23A4C96-E118-432A-AEFC-667EBE7C7E7A Q38377051-7A8B28F7-BCDC-4747-958F-3E78B363CD4A Q39231462-599A173A-D5E2-40F0-8A73-11AE34FF8982 Q40050910-12010D50-4C05-412E-87E6-BC902432FAC4 Q40117598-AD97A7B9-9FD1-40EE-A40E-B63290C096EC Q40722214-762F5684-8E62-4F98-9379-30F4D3F2216F Q45256524-506A6390-2C77-46CF-8249-3F08B54B238C

P2860

Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?

http://www.wikidata.org/entity/Q37392869

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 27 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Is the recommended dose of efa ...... iency virus-infected children?

@en

Is the recommended dose of efa ...... iency virus-infected children?

@nl

type

label

Is the recommended dose of efa ...... iency virus-infected children?

@en

Is the recommended dose of efa ...... iency virus-infected children?

@nl

prefLabel

Is the recommended dose of efa ...... iency virus-infected children?

@en

Is the recommended dose of efa ...... iency virus-infected children?

@nl

P1433

Q37392869-D8D5B4DE-796D-405A-B65C-344F06FED388

P1476

Q37392869-DC4FA551-07E6-4314-A7E3-376FD48CEA7D

P2093

Q37392869-072E535A-3060-4A4D-9151-1F3D5A1C57AD

Q37392869-24D510B5-11AF-4A5F-941E-B918FC5DCD48

Q37392869-2B504C93-610B-4DB2-A6DE-65513E2C1EBB

Q37392869-45F7DC82-A101-4BBC-AB46-2B910349463B

Q37392869-5EAC08AA-4B3F-4247-81A8-FB7AFCDF39B2

Q37392869-604C6BE7-EE3D-4DD7-BFCC-7E380C6E72E6

Q37392869-87DB6624-E870-4D08-9E53-E8A992E658E6

Q37392869-9E564249-316A-483C-B427-86548677B343

Q37392869-CFC8AF3E-1BE6-43FA-85AB-3AAD1FC85936

Q37392869-F7F5DA47-C9FD-4BA4-8263-3E3EDC1E1C73

P2860

Q37392869-05D9B47B-7D6C-412C-A946-2A0FF71CD1C2

Q37392869-07485A4A-07EB-47F9-ADBF-ECBC9B00B2F2

Q37392869-1C4858AE-689A-4B42-B5AA-6157A3C5E4AD

Q37392869-1E753067-7D38-482C-AEDA-A7CE0326EA92

Q37392869-23F973DA-DFD2-407A-80B7-3029FE2C9FB8

Q37392869-2672E93C-DC0C-4067-B54E-C5E56996BE3E

Q37392869-3054BFF3-6975-4113-AEE5-E37E036BBB1C

Q37392869-62973742-A664-4AE2-B62C-14A18D4F8065

Q37392869-62BFBFBF-6463-4AAC-8954-44DDE52748FE

Q37392869-685C2778-0786-476A-BB58-5BFAAF53F79F

P304

Q37392869-B58FB6DF-50B5-44E7-8CA6-924FA195927E

P31

Q37392869-DA49F2EB-1136-40F5-B2BA-CC1DDA4BFA55

P356

Q37392869-FCE72CDC-7581-4C24-9695-7CB958453A9C

P407

Q37392869-F42C04F0-879A-4C05-BB1E-3FD50796BCED

P433

Q37392869-EDB65D8C-15D1-4960-A52E-6747385E2E78

P478

Q37392869-B690BC4E-F0F5-446C-B982-E4262835E8AE

P50

Q37392869-47D6CF55-48E8-43EE-808E-6E160CA83D9E

Q37392869-80C174FD-11A4-459C-B2AA-6AB9727868E8

Q37392869-DB42F3A7-BC98-4FC0-A360-6FCC32F326E4

P577

Q37392869-8647F75A-8C9E-47C5-81A6-32AC359D54F2

P5875

Q37392869-362D757E-8624-4A56-A200-413A5FA2AC00

P698

Q37392869-27A52B35-5B2C-4864-8BA8-4592D87DFC9E

P932

Q37392869-E65D9A03-507B-4C81-A305-026CACA69236

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Is the recommended dose of efa ...... iency virus-infected children?

@en

P2093

Boubacar Nacro

http://www.w3.org/2001/XMLSchema#string

Déborah Hirt

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Zoure

http://www.w3.org/2001/XMLSchema#string

François Rouet

http://www.w3.org/2001/XMLSchema#string

Hervé Hien

http://www.w3.org/2001/XMLSchema#string

Hélène Peyrière

http://www.w3.org/2001/XMLSchema#string

Jean-Marc Tréluyer

http://www.w3.org/2001/XMLSchema#string

Mathieu Olivier

http://www.w3.org/2001/XMLSchema#string

Philippe Msellati

http://www.w3.org/2001/XMLSchema#string

Saik Urien

http://www.w3.org/2001/XMLSchema#string

P2860

Ways to fit a PK model with some data below the quantification limit.

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial

Once-a-day highly active antiretroviral therapy: a systematic review.

Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children.

Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test.

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.

Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.

Performance analysis of a rapid HPLC determination with the solvent demixing extraction of HIV antiproteases and efavirenz in plasma.

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

P304

4407-4413

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01594-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Philippe Van de Perre

Jean-Marc Tréluyer

P577

2009-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26698985

http://www.w3.org/2001/XMLSchema#string

P698

19635964

http://www.w3.org/2001/XMLSchema#string

P932

2764212

http://www.w3.org/2001/XMLSchema#string